Ethical Approval

This analysis was approved by the Institutional Review Boards of all participating sites.

Study Registration Clinical Trial Registration Number

Not applicable.

Disclosures/Conflict of Interest Statement

Dr Fudim was supported by the NIH, Alleviant, Gradient, Reprieve, Sardocor, and Doris Duke. He is a consultant and/or has ownership interest in Abbott, Acorai, Ajax, Alio Health, Alleviant, Artha, Astellas, Audicor, AxonTherapies, Bodyguide, Bodyport, Boston Scientific, Broadview, Cadence, Cardiosense, Cardioflow, Clinical Accelerator, CVRx, Daxor, Edwards LifeSciences, Echosens, EKO, Endotronix, Feldschuh Foundation, Fire1, FutureCardia, Gradient, Hatteras, HemodynamiQ, Impulse Dynamics, ISHI, Lumia Health, Medtronic, NovoNordisk, NucleusRx, Omega, Orchestra, Parasym, Pharmacosmos, Presidio, Procyreon, Proton Intelligence, Puzzle, ReCor, Scirent, SCPharma, Shifamed, Splendo, Summacor, SyMap, Terumo, Vascular Dynamics, Vifor Pharma, Vironix, Viscardia, Zoll. Dr. Miller received unrestricted research grant support from Daxor Corporation and the Feldschuh Foundation for Clinical Research. Dr. Yaranov received consulting fees from Daxor Corporation (Oak Ridge, TN, USA). Dr. Fudim is an editor in this journal. All other authors report no relevant disclosures.